These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20592407)

  • 1. Generalized white appearance of the oral mucosa. Hyperkeratosis secondary to palifermin.
    Lerman MA; Treister NS
    J Am Dent Assoc; 2010 Jul; 141(7):867-9. PubMed ID: 20592407
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversible painful oral mucosal hyperpigmentation following palifermin administration.
    Kaloyannidis P; Papalexandri A; Papaemanouil E; Papaioannou M; Sakellari I
    Acta Haematol; 2010; 124(3):185-7. PubMed ID: 20962520
    [No Abstract]   [Full Text] [Related]  

  • 3. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
    Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T; Shea T; Yanovich S; Hansen K; Noga S; McCarty J; LeMaistre CF; Sung EC; Blazar BR; Elhardt D; Chen MG; Emmanouilides C
    N Engl J Med; 2004 Dec; 351(25):2590-8. PubMed ID: 15602019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of palifermin on mucosal toxicity in autologous stem cell transplants using busulfan-melphalan conditioning chemotherapy for Hodgkin and non-Hodgkin lymphoma.
    Campbell P; Friebe A; Foulstone P; Grigg A; Hempton J; Bajel A
    Leuk Lymphoma; 2012 Jul; 53(7):1415-6. PubMed ID: 22204452
    [No Abstract]   [Full Text] [Related]  

  • 5. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.
    Vadhan-Raj S; Trent J; Patel S; Zhou X; Johnson MM; Araujo D; Ludwig JA; O'Roark S; Gillenwater AM; Bueso-Ramos C; El-Naggar AK; Benjamin RS
    Ann Intern Med; 2010 Sep; 153(6):358-67. PubMed ID: 20855800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial.
    Lucchese A; Matarese G; Manuelli M; Ciuffreda C; Bassani L; Isola G; Cordasco G; Gherlone E
    Minerva Stomatol; 2016 Feb; 65(1):43-50. PubMed ID: 26862696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Summaries for patients. Palifermin can prevent severe oral mucositis during chemotherapy.
    Ann Intern Med; 2010 Sep; 153(6):I-44. PubMed ID: 20855786
    [No Abstract]   [Full Text] [Related]  

  • 8. Transient oral cavity and skin complications after mucositis preventing therapy (palifermin) in a patient after allogeneic PBSCT. Case history.
    Grzegorczyk-Jaźwińska A; Kozak I; Karakulska-Prystupiuk E; Rokicka M; Ganowicz E; Dwilewicz-Trojaczek J; Górska R
    Adv Med Sci; 2006; 51 Suppl 1():66-8. PubMed ID: 17460832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.
    Goldberg JD; Zheng J; Castro-Malaspina H; Jakubowski AA; Heller G; van den Brink MR; Perales MA
    Bone Marrow Transplant; 2013 Jan; 48(1):99-104. PubMed ID: 22750997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant.
    Beaven AW; Shea TC
    Drugs Today (Barc); 2007 Jul; 43(7):461-73. PubMed ID: 17728847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting.
    Stiff PJ; Emmanouilides C; Bensinger WI; Gentile T; Blazar B; Shea TC; Lu J; Isitt J; Cesano A; Spielberger R
    J Clin Oncol; 2006 Nov; 24(33):5186-93. PubMed ID: 16391299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palifermin: in myelotoxic therapy-induced oral mucositis.
    Siddiqui MA; Wellington K
    Drugs; 2005; 65(15):2139-46; discussion 2147-9. PubMed ID: 16225371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.
    Langner S; Staber P; Schub N; Gramatzki M; Grothe W; Behre G; Rabitsch W; Urban C; Linkesch W; Neumeister P
    Bone Marrow Transplant; 2008 Aug; 42(4):275-9. PubMed ID: 18500368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience.
    Keefe D; Lees J; Horvath N
    Support Care Cancer; 2006 Jun; 14(6):580-2. PubMed ID: 16775651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia.
    Lucchese A; Matarese G; Ghislanzoni LH; Gastaldi G; Manuelli M; Gherlone E
    Leuk Lymphoma; 2016; 57(4):820-7. PubMed ID: 26428409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palifermin: new drug. Prevention of oral mucositis: inappropriate evaluation.
    Prescrire Int; 2007 Aug; 16(90):135-8. PubMed ID: 17724832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palifermin as primary mucositis prophylaxis in patients with B-cell Non-Hodgkin lymphoma: a case series.
    Zembillas AS; Thomas SM; Rotz SJ; Buhtoiarov IN; Hanna R
    Pediatr Hematol Oncol; 2022 Feb; 39(1):80-82. PubMed ID: 34003714
    [No Abstract]   [Full Text] [Related]  

  • 18. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
    Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
    J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevention of oral mucositis in patients with blood cancers: current concepts and emerging landscapes.
    Niscola P; Tendas A; Cupelli L; Catalano G; Scaramucci L; Giovannini M; Trinchieri V; Sharma A; Efficace F; Cartoni C; Piccioni D; Perrotti A; Dentamaro T; de Fabritiis P; Keefe DM
    Cardiovasc Hematol Agents Med Chem; 2012 Dec; 10(4):362-75. PubMed ID: 22721442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis.
    McDonnell AM; Lenz KL
    Ann Pharmacother; 2007 Jan; 41(1):86-94. PubMed ID: 17190850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.